ABUS - Pambiji Buku Bisnis Arbutus Biopharma Corporation

The retrospective value of Arbutus Biopharma (ABUS) shares on the GURU.Markets platform is based on the ownership of a proprietary LNP platform for hepatitis B therapy, which creates barriers for partners. The current indicator stands at 0.26, while the lack of sales and a lengthy path to FDA approval are triggering an exodus of venture capital. Intellectual property litigation and the development of RNA-based drugs remain the primary growth catalysts.

ABUS Kapitalisasi Buku Tekmira Pharmaceuticals (04.07.2022 - 28.10.2026)

Rincian metrik lan analitis perusahaan Arbutus Biopharma Corporation (ABUS)

- rega lan prakiraan konsensus rega:

Rega saham Tekmira Pharmaceuticals|ABUS - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar Arbutus Biopharma Corp|ABUS - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Buku Saham Arbutus Biopharma|ABUS - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku arbutusbio.com|ABUS - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Arbutus Biopharma|ABUS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Arbutus Biopharma Corp|ABUS - Utang perusahaan|Utang marang nilai buku Arbutus Biopharma Corp|ABUS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Arbutus Biopharma

Pambiji fundamental:ABUS - Tekmira Pharmaceuticals

Investors value Arbutus Biopharma (ABUS) based on the potential of its lipid nanoparticle patents and hepatitis B therapy. This metric reflects the real value of the business by subtracting total liabilities from total assets. Analyzing the net assets chart at book value allows investors to filter out market noise and overvaluation. This metric captures the internal capital supporting the company's development. Fundamental value serves as a defensive filter against speculative price volatility.

Analisis pesaing Arbutus Biopharma